Amylyx PharmaceuticalsAMLX -1.06%33 EBIT per Share is $-1.60 as of Mar. 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 810 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks better than 71.36% on this metric.
Amylyx Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.40.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.60.
During the past 3 years, the average EBIT per Share Growth Rate was 22.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Amylyx Pharmaceuticals's EBIT per Share or its related term are showing as below:
AMLX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -126 Med: -35.8 Max: 22.2
Current: 22.2
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Amylyx Pharmaceuticals was 22.20% per year. The lowest was -126.00% per year. And the median was -35.80% per year.
AMLX's 3-Year EBIT Growth Rate is ranked better than 71.36% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs AMLX: 22.20
Amylyx Pharmaceuticals (NAS:AMLX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Amylyx Pharmaceuticals EBIT per Share Related Terms
Amylyx Pharmaceuticals EBIT per Share Historical Data
* Premium members only.
The historical data trend for Amylyx Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (AMLX) has a EBIT per Share of $-1.60 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Amylyx Pharmaceuticals and its competitors. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #232 out of 810 companies in the Drug Manufacturers industry, placing it in the top 28.6%.
Is Amylyx Pharmaceuticals' EBIT per Share too high?
Amylyx Pharmaceuticals' current EBIT per Share is $-1.60. Based on the distribution chart, Amylyx Pharmaceuticals ranks #232 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' EBIT per Share compare to ANIP and TRLV?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #232 out of 810 companies for EBIT per Share. This puts Amylyx Pharmaceuticals in the upper half of its industry. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Amylyx Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current EBIT per Share is $-1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current EBIT per Share of $-1.60. The current EBIT per Share is $-1.60. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current EBIT per Share is $-1.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
